ImmunoPrecise Antibodies (IPA) announced a strategic collaboration with Ribopro. This collaboration seeks to revolutionize the discovery and development of therapeutic antibodies by integrating ...
This collaboration seeks to revolutionize the discovery and development of therapeutic antibodies by integrating RIBOPRO’s advanced mRNA-based antigen expression expertise with IPA’s in silico ...
ImmunoPrecise Antibodies (IPA) has entered a strategic partnership with Ribopro to transform therapeutic antibody discovery and development. The partnership will combine the mRNA [messenger ...
AUSTIN, Texas–(BUSINESS WIRE)–$IPA #AI–ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody ...
AUSTIN, Texas, February 26, 2025--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today ...
AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback